Hiromi Sano
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Hiromi Sano has a total of 74 co-authors. Here are the top co-authors by number of shared publications:
A. Kanamori
1 shared publicationAi Kanemaru
K.K. DNAFORM, Yokohama, Japan
1 shared publication- Akari Suzuki
Laboratory for Autoimmune Diseases, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan
1 shared publication - Akifumi Takaori-Kondo
Department of Hematology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
1 shared publication - Akiko Oguchi
RIKEN Center for Integrative Medical Sciences, Yokohama 230-0045, Japan
1 shared publication - Chikashi Terao
Laboratory for Statistical and Translational Genetics, RIKEN Center for Integrative Medical Sciences
1 shared publication
Latest Publications
- Open Access
- 22 December 2024
- Published by Wiley in Brain and Behavior
- Vol. 14 (12) , e70184
Seasonal Variations in Triptan Prescription in Japan: A Nationwide Time‐Series Analysis
Objective: This study aimed to investigate seasonal differences in migraine onset in Japan and associated trends in the prescription of triptan.Background: The relationship between seasonal changes and the onset of migraine remains largely unknown.Methods: We combined the large‐scale medical claims data in Japan with city‐level meteorological data presented by the Japan Weather Association. The study period was from January 2018 to December 2019. We included patients aged 18–74 years and diagnosed with migraine who had been prescribed triptans in 2018. Patients were categorized into four groups according to the seasons when they were prescribed medicines: winter (January–March), spring (April–June), summer (July–September), and autumn (October–December). Migraine onsets were defined by the time of triptan prescription. The least‐square mean differences between the seasons were estimated with linear mixed‐effects models for repeated measures, adjusting for the following covariates: sex, age, acute migraine medications, and medications for migraine prevention, comorbidities that can induce migraine, other comorbidities, and the estimated age of menopause in females.Results: We analyzed data of 12,986 patients in 2019 after triptan had been prescribed (female 74.1%). The mean age was 44.1 years. The mean number of amounts of prescriptions comprised 2.12 tablets/month in spring and summer, whereas there were only 2.09 tablets/month in autumn and 2.00 tablets/month in winter. The amount of triptan prescribed in winter was lower than in spring (β = −0.117; 95% confidence interval [CI]: −0.169 to −0.065).Conclusion: The study results suggest that seasons can have an impact on the onset of migraine; thus, clinicians may advise patients to take preventive actions, including self‐care and drug therapies, from the winter stage. This should be done in order to reduce the number of migraine onsets in high‐risk season (spring) regardless of region.
- 22 December 2024
- Published by Wiley in Brain and Behavior
- Vol. 14 (12) , e70184
Open AccessSeasonal Variations in Triptan Prescription in Japan: A Nationwide Time‐Series Analysis
Objective: This study aimed to investigate seasonal differences in migraine onset in Japan and associated trends in the prescription of triptan.Background: The relationship between seasonal changes and the onset of migraine remains largely unknown.Methods: We combined the large‐scale medical claims data in Japan with city‐level meteorological data presented by the Japan Weather Association. The study period was from January 2018 to December 2019. We included patients aged 18–74 years and diagnosed with migraine who had been prescribed triptans in 2018. Patients were categorized into four groups according to the seasons when they were prescribed medicines: winter (January–March), spring (April–June), summer (July–September), and autumn (October–December). Migraine onsets were defined by the time of triptan prescription. The least‐square mean differences between the seasons were estimated with linear mixed‐effects models for repeated measures, adjusting for the following covariates: sex, age, acute migraine medications, and medications for migraine prevention, comorbidities that can induce migraine, other comorbidities, and the estimated age of menopause in females.Results: We analyzed data of 12,986 patients in 2019 after triptan had been prescribed (female 74.1%). The mean age was 44.1 years. The mean number of amounts of prescriptions comprised 2.12 tablets/month in spring and summer, whereas there were only 2.09 tablets/month in autumn and 2.00 tablets/month in winter. The amount of triptan prescribed in winter was lower than in spring (β = −0.117; 95% confidence interval [CI]: −0.169 to −0.065).Conclusion: The study results suggest that seasons can have an impact on the onset of migraine; thus, clinicians may advise patients to take preventive actions, including self‐care and drug therapies, from the winter stage. This should be done in order to reduce the number of migraine onsets in high‐risk season (spring) regardless of region.
- 5 July 2024
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 385 (6704) , eadd8394
An atlas of transcribed enhancers across helper T cell diversity for decoding human diseases
Transcribed enhancer maps can reveal nuclear interactions underpinning each cell type and connect specific cell types to diseases. Using a 5′ single-cell RNA sequencing approach, we defined transcription start sites of enhancer RNAs and other classes of coding and noncoding RNAs in human CD4 + T cells, revealing cellular heterogeneity and differentiation trajectories. Integration of these datasets with single-cell chromatin profiles showed that active enhancers with bidirectional RNA transcription are highly cell type–specific and that disease heritability is strongly enriched in these enhancers. The resulting cell type–resolved multimodal atlas of bidirectionally transcribed enhancers, which we linked with promoters using fine-scale chromatin contact maps, enabled us to systematically interpret genetic variants associated with a range of immune-mediated diseases.
- 5 July 2024
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 385 (6704) , eadd8394
An atlas of transcribed enhancers across helper T cell diversity for decoding human diseases
Transcribed enhancer maps can reveal nuclear interactions underpinning each cell type and connect specific cell types to diseases. Using a 5′ single-cell RNA sequencing approach, we defined transcription start sites of enhancer RNAs and other classes of coding and noncoding RNAs in human CD4 + T cells, revealing cellular heterogeneity and differentiation trajectories. Integration of these datasets with single-cell chromatin profiles showed that active enhancers with bidirectional RNA transcription are highly cell type–specific and that disease heritability is strongly enriched in these enhancers. The resulting cell type–resolved multimodal atlas of bidirectionally transcribed enhancers, which we linked with promoters using fine-scale chromatin contact maps, enabled us to systematically interpret genetic variants associated with a range of immune-mediated diseases.
- Open Access
Characteristics of patients who seek medical attention for headache and those who do not: cross-sectional survey and linked medical claims data analysis in Japan
Objective To describe the characteristics of patients who sought medical attention for headache and those who did not. Design This observational study used a cross-sectional online survey and linked medical claims data. Setting Data from an online self-administered questionnaire survey conducted in November 2020 as well as linked medical claims data spanning December 2017 and November 2020 were provided by DeSC Healthcare Inc. Participants Of 21 480 respondents aged 19–74 years whose sex and age data matched the claims data, 7311 reported experiencing headache. Measures Outcomes included participant characteristics, status of medical attention seeking, medication use, quality of life (QOL) measured by Migraine-Specific QOL (MSQ) questionnaire V.2.1 and headache intensity. Results Of the 7311 respondents with headache, 735 sought medical attention and 6576 did not. Compared with those who did not seek medical attention, those who sought medical attention had more frequent headaches (median: 5 days/3 months vs 10 days/3 months in those who did not vs those who sought medical attention, respectively) had lower MSQ score (mean (SD) MSQ total score: 87.6 (13.0) vs 77.1 (18.1)) and were likely to experience moderately severe to severe headache (19.0% (1252/6576) vs 41.2% (303/735)) without headache medication. The inability to tolerate headache (36.5% (268/735)) was a common reason for seeking medical attention. Since the pain was not severe enough, 35.3% (2323/6576) of patients did not seek medical attention. Furthermore, a subgroup of respondents experiencing headache for ≥15 days were uncertain about which hospital or department to attend. Conclusions Patients typically seek help when the pain becomes unbearable. Still, some of them did not seek medical attention while they were experiencing headache for ≥15 days per month. Therefore, it is important to raise awareness and encourage seeking early medical attention before symptoms and associated burdens become too severe to be managed effectively.
Open AccessCharacteristics of patients who seek medical attention for headache and those who do not: cross-sectional survey and linked medical claims data analysis in Japan
Objective To describe the characteristics of patients who sought medical attention for headache and those who did not. Design This observational study used a cross-sectional online survey and linked medical claims data. Setting Data from an online self-administered questionnaire survey conducted in November 2020 as well as linked medical claims data spanning December 2017 and November 2020 were provided by DeSC Healthcare Inc. Participants Of 21 480 respondents aged 19–74 years whose sex and age data matched the claims data, 7311 reported experiencing headache. Measures Outcomes included participant characteristics, status of medical attention seeking, medication use, quality of life (QOL) measured by Migraine-Specific QOL (MSQ) questionnaire V.2.1 and headache intensity. Results Of the 7311 respondents with headache, 735 sought medical attention and 6576 did not. Compared with those who did not seek medical attention, those who sought medical attention had more frequent headaches (median: 5 days/3 months vs 10 days/3 months in those who did not vs those who sought medical attention, respectively) had lower MSQ score (mean (SD) MSQ total score: 87.6 (13.0) vs 77.1 (18.1)) and were likely to experience moderately severe to severe headache (19.0% (1252/6576) vs 41.2% (303/735)) without headache medication. The inability to tolerate headache (36.5% (268/735)) was a common reason for seeking medical attention. Since the pain was not severe enough, 35.3% (2323/6576) of patients did not seek medical attention. Furthermore, a subgroup of respondents experiencing headache for ≥15 days were uncertain about which hospital or department to attend. Conclusions Patients typically seek help when the pain becomes unbearable. Still, some of them did not seek medical attention while they were experiencing headache for ≥15 days per month. Therefore, it is important to raise awareness and encourage seeking early medical attention before symptoms and associated burdens become too severe to be managed effectively.
- Open Access
- 1 March 2021
- Published by Taylor & Francis in Neuropsychiatric Disease and Treatment
- Vol. ume 17, 821-833
Real-World Treatment Patterns and Adherence to Oral Medication Among Patients with Bipolar Disorders: A Retrospective, Observational Study Using a Healthcare Claims Database
Purpose: This study aimed to describe real-world treatment patterns and medication adherence among patients with bipolar disorder (BD) in Japan. Patients and Methods: Adult patients with a BD diagnosis were identified between July 2013 and February 2018, using an employment-based health insurance claims database from the JMDC Inc. Treatment patterns of target drugs (mood stabilizers, antipsychotics) and adherence (measured by the proportion of days covered [PDC]) were assessed during the first- through third-year follow-up. Adherence was also assessed for patient subgroups. Results: The analyzed population included 13,788 patients with BD. They were mostly prescribed sodium valproate, lithium, or aripiprazole (range: 21.1– 27.4%) across 3 years of follow-up, whereas lamotrigine was prescribed to 11.2– 12.8% of patients. Benzodiazepines (70– 87%) and antidepressants (52– 71%) were commonly prescribed during all three follow-up periods. The mean PDC among all patients with BD was 0.51 during the first and increased to 0.61 during the third year. The mean PDC was 0.42 (first year) in patients aged < 30 years and 0.49 in those aged 30– 40 years. The PDC was 0.44– 0.61 (depending on the drug class) in those who were prescribed a single-class target drug and 0.68– 0.83 in those prescribed two drug classes concomitantly. Conclusion: This study documented generally low medication adherence among patients with BD, and those at young age. These patients may require more attention.
- 1 March 2021
- Published by Taylor & Francis in Neuropsychiatric Disease and Treatment
- Vol. ume 17, 821-833
Open AccessReal-World Treatment Patterns and Adherence to Oral Medication Among Patients with Bipolar Disorders: A Retrospective, Observational Study Using a Healthcare Claims Database
Purpose: This study aimed to describe real-world treatment patterns and medication adherence among patients with bipolar disorder (BD) in Japan. Patients and Methods: Adult patients with a BD diagnosis were identified between July 2013 and February 2018, using an employment-based health insurance claims database from the JMDC Inc. Treatment patterns of target drugs (mood stabilizers, antipsychotics) and adherence (measured by the proportion of days covered [PDC]) were assessed during the first- through third-year follow-up. Adherence was also assessed for patient subgroups. Results: The analyzed population included 13,788 patients with BD. They were mostly prescribed sodium valproate, lithium, or aripiprazole (range: 21.1– 27.4%) across 3 years of follow-up, whereas lamotrigine was prescribed to 11.2– 12.8% of patients. Benzodiazepines (70– 87%) and antidepressants (52– 71%) were commonly prescribed during all three follow-up periods. The mean PDC among all patients with BD was 0.51 during the first and increased to 0.61 during the third year. The mean PDC was 0.42 (first year) in patients aged < 30 years and 0.49 in those aged 30– 40 years. The PDC was 0.44– 0.61 (depending on the drug class) in those who were prescribed a single-class target drug and 0.68– 0.83 in those prescribed two drug classes concomitantly. Conclusion: This study documented generally low medication adherence among patients with BD, and those at young age. These patients may require more attention.
- 1 January 2002
- Published by Taylor & Francis in Scandinavian Journal of Gastroenterology
- Vol. 37 (3) , 279-286
Gastrin and Helicobacter pylori in Low-grade MALT Lymphoma Patients
Background: This study of patients with Helicobacter pylori infection and low-grade MALT lymphoma aimed to investigate: 1) the effect of H. pylori eradication therapy on the serum gastrin level, 2) whether changes of the serum gastrin level after therapy could predict the prognosis of patients with this tumour, and 3) the relationship between the gastric H. pylori load, the serum gastrin level and the status of MALT lymphoma. Methods: Thirteen patients with documented low-grade MALT lymphoma and H. pylori infection were enrolled and received H. pylori eradication therapy as the sole initial treatment. The presence of H. pylori , the serum gastrin level, the endoscopic findings, the pathologic features of the biopsies and resected specimens, and the endoscopic ultrasonography findings were evaluated before and after therapy. Follow-up was carried out every 3-6 months. Results: H. pylori eradication was eventually achieved in all 13 patients. The pretreatment fasting serum gastrin level decreased from 177.1 ± 107.4 pg/ml to 129.2 ± 78.1, 96.4 ± 66.6 and 80.1 ± 42.7 pg/ml after 0-3, 3-6 and 6-9 months, respectively (all P < 0.05). Successful eradication of H. pylori was followed by a decrease of the fasting serum gastrin level and complete regression of initial low-grade MALT lymphoma was observed in all patients. However, two patients subsequently developed recurrent high-grade MALT lymphoma or high-grade lymphoma. In one of them, the serum gastrin level rose again above the pretreatment value. In the other, however, the fasting gastrin level fell throughout the study period. The median fasting serum gastrin level before H. pylori eradication therapy was higher in the patients with tumours of the gastric body (203.4 ± 108.9 pg/ml) than in those with tumours of the antrum and angulus (89.3 ± 28.0 pg/ml) ( P = 0.06). Conclusions: Hypergastrinaemia may be associated with an increased risk of gastric MALT lymphoma.
- 1 January 2002
- Published by Taylor & Francis in Scandinavian Journal of Gastroenterology
- Vol. 37 (3) , 279-286
Gastrin and Helicobacter pylori in Low-grade MALT Lymphoma Patients
Background: This study of patients with Helicobacter pylori infection and low-grade MALT lymphoma aimed to investigate: 1) the effect of H. pylori eradication therapy on the serum gastrin level, 2) whether changes of the serum gastrin level after therapy could predict the prognosis of patients with this tumour, and 3) the relationship between the gastric H. pylori load, the serum gastrin level and the status of MALT lymphoma. Methods: Thirteen patients with documented low-grade MALT lymphoma and H. pylori infection were enrolled and received H. pylori eradication therapy as the sole initial treatment. The presence of H. pylori , the serum gastrin level, the endoscopic findings, the pathologic features of the biopsies and resected specimens, and the endoscopic ultrasonography findings were evaluated before and after therapy. Follow-up was carried out every 3-6 months. Results: H. pylori eradication was eventually achieved in all 13 patients. The pretreatment fasting serum gastrin level decreased from 177.1 ± 107.4 pg/ml to 129.2 ± 78.1, 96.4 ± 66.6 and 80.1 ± 42.7 pg/ml after 0-3, 3-6 and 6-9 months, respectively (all P < 0.05). Successful eradication of H. pylori was followed by a decrease of the fasting serum gastrin level and complete regression of initial low-grade MALT lymphoma was observed in all patients. However, two patients subsequently developed recurrent high-grade MALT lymphoma or high-grade lymphoma. In one of them, the serum gastrin level rose again above the pretreatment value. In the other, however, the fasting gastrin level fell throughout the study period. The median fasting serum gastrin level before H. pylori eradication therapy was higher in the patients with tumours of the gastric body (203.4 ± 108.9 pg/ml) than in those with tumours of the antrum and angulus (89.3 ± 28.0 pg/ml) ( P = 0.06). Conclusions: Hypergastrinaemia may be associated with an increased risk of gastric MALT lymphoma.
- Open Access
- 1 January 1995
- Published by Japan Society for Clinical Anesthesia in THE JOURNAL OF JAPAN SOCIETY FOR CLINICAL ANESTHESIA
- Vol. 15 (4) , 326-329
Pain Relief in a Pregnant Woman with Extradural Cyst in the Sacral Region.
- 1 January 1995
- Published by Japan Society for Clinical Anesthesia in THE JOURNAL OF JAPAN SOCIETY FOR CLINICAL ANESTHESIA
- Vol. 15 (4) , 326-329
Open AccessPain Relief in a Pregnant Woman with Extradural Cyst in the Sacral Region.